A novel anoikis-related signature predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma

Mingze Guan ¹, Hua Zhao ¹, Qi Zhang ¹

⁰Department of Hematology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China.

Expert Review of Molecular Diagnostics +

|

May 6, 2024

View abstract on PubMed

Summary

A new risk signature based on anoikis-related genes (ARGs) can predict prognosis and guide treatment for diffuse large B cell lymphoma (DLBCL). This signature identifies high-risk DLBCL patients who may benefit from specific therapies like doxorubicin and gemcitabine.

Area Of Science

Oncology
Genomics
Bioinformatics

Background

Anoikis, a form of programmed cell death, is implicated in cancer metastasis but understudied in diffuse large B cell lymphoma (DLBCL).
Understanding anoikis' role in DLBCL is crucial for developing novel therapeutic strategies.

Purpose Of The Study

To develop and validate an anoikis-related gene (ARG)-based risk signature for DLBCL.
To assess the signature's prognostic value and its correlation with drug sensitivity in DLBCL patients.

Main Methods

RNA sequencing and clinical data were analyzed from the GEO database.
An ARG-based risk signature was constructed and validated across multiple cohorts.
Drug sensitivity (IC50) was predicted using bioinformatics and confirmed with cytotoxicity assays.

Main Results

The high-risk group identified by the signature exhibited poorer prognosis and an immunosuppressive tumor microenvironment in DLBCL.
A nomogram incorporating eight variables demonstrated superior prognostic accuracy compared to the international prognostic index.
Patients in the high-risk group showed increased sensitivity to doxorubicin and gemcitabine, while the low-risk group was more sensitive to cisplatin and dasatinib.

Conclusions

The ARG-based signature serves as a valuable tool for predicting prognosis in DLBCL.
This signature offers potential for optimizing treatment strategies by identifying patient subgroups with differential drug sensitivities.

Keywords:

Diffuse large B-cell lymphoma anoikis drug sensitivity immune infiltration prognostic signature